Tumor MicroenvironmentProfiling the Tumor Microenvironment

Using a genomics based approach to analyze the tumor microenvironment can provide unique insights beyond IHC and FACS methods. OncoPeptTUME deeply interrogates RNA-Seq data sets to produce high resolution mapping of the tumor microenvironment using proprietary cell type specific gene expression signatures. OncoPeptTUME provides a critical assessment of the inflammatory microenvironment that modulates T-cell infiltration and its anti-tumor activities to enable better prediction of treatment response and efficacy.

Discover OncoPeptTUME

A powerful end-to-end service to analyze the tumor microenvironment compatible with varying quantity and quality samples

Preclinical Research, Drug DiscoveryPre-Clinical

  • Discover biomarkers for patient stratification
  • High resolution mapping of gene expression in the tumor and stromal compartments

Clinical ResearchClinical

  • Discover biomarkers for patient selection
  • Monitor durability of response
  • Accurate quantification of biomarkers before and after drug treatment

Drug ApprovalPost Approval

  • Analyze patient outcome
  • Evaluation of drug resistance
  • Discover novel drug targets to increase efficacy and reduce toxicity

Critical Insights at Specific Stages of the Cancer Immunity Cycle

OncoPeptTUME Workflow Highlights

  • Requires low sample input from FFPE or fresh frozen tissues compared to IHC or FACS
  • High throughput and robust workflow at significantly lower cost than IHC and FACS
  • Provides an accurate representation of the tumor microenvironment at a cellular, molecular and biochemical level
  • Shorter analysis time with high information content and less variability in data
  • Can be customized to fit cancer immunotherapy project needs and tailored to perform in preclinical and clinical settings
  • Continuously updated to include new insights from cancer immunotherapy basic and translational research

BioFX OncoPeptTUME Analysis

  • Streamlined pipeline for fast & scalable analysis
  • Customized reporting
  • Interactive reports
  • Publication-ready figures
  • Improve data interpretation with support from Medgenome’s team of experts


Explore Analysis Reports

OncoPepTUME pipeline quantifies the relative infiltration of innate and adaptive immune cells (CD8+, CD4+, T cells, B cells, Treg cells, NK cells, Macrophages, Monocytes, Neutrophils) with proprietary immune cell type-specific gene expression signatures.

Identify biomarkers for patient selection, predict likelihood of response to checkpoint inhibitor therapies and monitor durability of response.


Ordering and Data Delivery

MedGenome's customer portal allows for easy sample submission and sample tracking during lab processing. Data QC, raw data and interactive analysis reports are delivered securely through customer portal.


White Papers and Technical Resources

OncoPeptTUMETM — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications

Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide sustainable and long-lasting benefit in a few. Recently, significant efforts have been devoted to understanding the factors that influence response to immuno-therapy and/or contribute to the development of resistance to therapy. While it is appreciated that many different tumor cell- intrinsic and extrinsic features, including the tumor microenvironment, driver gene mutations, host genetics, microbiome and environmental factors modulate response to immune checkpoint inhibitors, the tumor microenvironment ecosystem could be a major contributor in regulating response to immunotherapy and development of resistance.


2023 © MedGenome • All Rights Reserved
Request a Quote